A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease Experiencing End of Dose "Wearing-Off"

Trial Profile

A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease Experiencing End of Dose "Wearing-Off"

Discontinued
Phase of Trial: Phase III

Latest Information Update: 27 Mar 2018

At a glance

  • Drugs Tozadenant (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Sponsors Biotie Therapies Corp.
  • Most Recent Events

    • 13 Dec 2017 Planned End Date changed from 31 Jul 2019 to 5 Jan 2018.
    • 13 Dec 2017 Planned primary completion date changed from 31 Jul 2019 to 5 Jan 2018.
    • 20 Nov 2017 Status changed from suspended to discontinued, according to an Acorda Therapeutics media release. The company is discontinuing dosing of all participants based on previously disclosed agranulocytosis and associated serious adverse events. the Company concluded that it could not be confident that weekly white blood cell count screening would sufficiently ensure patient safety.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top